Recent moves in the yogurt segment from CPG giants signal a strong category foundation heading into an uncertain economic future—a white horse amid other stagnating retail categories. Danone, for example, beat out analyst expectations with its Q1 sales.
Gen Z is redefining alcohol consumption with “zebra striping,” a trend where individuals alternate between alcoholic and non-alcoholic beverages during social outings, effectively halving their intake while embracing a sober-curious mindset. This shift presents unique opportunities for F&B brands to innovate.
The popularity of GLP-1 medications is compelling brands to innovate with smarter portion sizes and functional ingredients. This shift represents a revolutionary convergence of biotech, nutrition science, and consumer demand, reshaping how food supports appetite management and metabolic health.
This week, Natural Products Expo West 2025 showcased trends in the natural and organic sectors from nearly 3,200 exhibitors. The show especially highlighted the impact of GLP-1 drugs on snacking habits.
The growing popularity of GLP-1 weight-loss drugs is reshaping the yogurt market, as consumers increasingly seek protein-packed snacks. Multiple brands are innovating with high-protein, low-sugar options.
Despite recent challenges, the plant-based sector is primed for growth in some respects, with opportunities to innovate through functional ingredients, whole-food formulations, and clean-label transparency.
The latest FI Fast Break news podcast touches on the recent struggles of Noodles & Company, according to an industry turnaround expert.
The rapid adoption of weight-loss drugs is reshaping purchasing habits. Circana experts highlight opportunities for brands to align with GLP-1 users’ goals by offering tailored, portion-controlled products and leveraging personalized marketing strategies to capture this evolving market.
Alcohol manufacturers, retailers, and foodservice segments have a lot to worry about heading into the new year, with Dry January and Surgeon General advisories advocating for sober-curious lifestyles. Time will tell if these movements make an impact.
GLP-1 weight-loss drugs are transforming dieting culture, offering a relatively easy solution to weight loss. While these drugs may disrupt food consumption patterns, their long-term impact hinges on overcoming high dropout rates and premium pricing, one industry insider says.
With dreams of CPG integration, FitBiomics is producing probiotics designed by data mining the gut microbiomes of professional athletes. Is this the next big wellness trend?
The juice market is struggling as consumers increasingly seek healthier options. Experts at one recent industry event emphasized the need for brands to seize upon trends like sugar reduction.
The latest Fast Break news podcast touches on PepsiCo’s acquisition of a Mexican-American brand and what that says about consumer demand.
Nutrition plays a crucial role when taking GLP-1 medication for weight loss, which has transformed medical approaches to managing obesity.
The latest FI Fast Break news podcast touches on Target’s plans to reduce prices on several items this summer.
New research, conducted by food innovation firm Mattson, revealed that GLP-1 users have reported specific food preferences, including more protein and smaller portions.
From GLP-1 injectables to mushroom-based coffee alternatives, the booming supplement market is making nutrition easier to manipulate.
The recent rise of Ozempic and other weight-loss drugs started with blowout results that drove shares of their manufacturers higher, then wound up cascading across seemingly disparate sectors. In 2023, Novo Nordisk, the manufacturer of …
Eli Lilly’s Zepbound, recently approved by the FDA, is the most potent weight-loss drug yet. Could it impact the food industry? At least one expert says ‘yes.’
Several medications approved to treat diabetes are being used as “miracle” weight-loss drugs, and the category continues to grow.
